A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

Trial Profile

A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Ridinilazole (Primary) ; Vancomycin
  • Indications Clostridium-difficile-infections
  • Focus Therapeutic Use
  • Acronyms Ri-CoDIFy 2
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 11 Jul 2018 Status changed from planning to not yet recruiting.
    • 27 Mar 2018 According to a Summit Therapeutics media release, this trial is planned to initiate in the Q1 2019.
    • 29 Mar 2017 According to a Summit Therapeutics media release, this trial is planned to initiate in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top